Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • sikidiri
    Member
    • May 2011
    • 13

    #1

    Analysis of Gro-seq data

    I want to analyse a published gro-seq data. But I am new to it.
    I want to see the direction of transcripts. For this, do I need to separate the positive and negative tags and then map them on to the human genome?
    Please advise me.
    Thanks.
  • steven
    Senior Member
    • Aug 2009
    • 269

    #2
    I'd say that the "positive" or "negative" strand information is precisely supposed to come from the alignment.

    Comment

    • sikidiri
      Member
      • May 2011
      • 13

      #3
      Thanks for you reply. I have already the aligned reads in bed format. I want to see these tags on the human genome e.g at the TSS and want to see the direction of the tags. Do I need to segregate the sense and antisense genes or shall I segregate the tags based upon the strand?

      Comment

      • steven
        Senior Member
        • Aug 2009
        • 269

        #4
        if there is a strand information specified in your BED ("+" or "-" in the 6th column) then it should be easy to compare the reads with some gene annotation. The idea would be to compare
        - the positions of the reads vs. the positions of the annotated exons to assign reads to genes
        - the strand info of the reads vs. the strand of the corresponding gene to assign a "sense" or "antisense" label to each read
        Look e.g. for "BEDtools" (and send me a PM if you don't find)

        Comment

        • sikidiri
          Member
          • May 2011
          • 13

          #5
          Hello,
          0


          I have two chip-seq samples for the same protein in embryonic stem (ES) cells and rationic acid induced cells. I have obtained around 800 peaks in ES cells and around 7500 peaks in induced cells. Protocol, antibody, peak calling paramteres (MACS) and the person who has done the the experiments are all same. Number of reads obtained in both the samples is similar with similar level of background. If I see peaks in my new dataset, it has good enrichment as compared to the old one at the same region (~50% higher enrichment). I want to know, is this the real biological difference or because of deep sequencing, in the new data set I see good enrichment of tags which is not seen in the old dataset. How to rule out any technical problems, if there are any? Any suggestions are most welcome. Thanks.

          Comment

          Latest Articles

          Collapse

          • SEQadmin2
            Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
            by SEQadmin2


            Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

            The systematic characterization of the human proteome has
            ...
            07-20-2026, 11:48 AM
          • SEQadmin2
            Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
            by SEQadmin2



            Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
            ...
            07-09-2026, 11:10 AM
          • SEQadmin2
            Cancer Drug Resistance: The Lingering Barrier to Rising Survival
            by SEQadmin2



            Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.

            There is no single reason why many patients don’t respond to treatment as expected. Cancer is...
            07-08-2026, 05:17 AM

          ad_right_rmr

          Collapse

          News

          Collapse

          Topics Statistics Last Post
          Started by SEQadmin2, Today, 02:55 AM
          0 responses
          4 views
          0 reactions
          Last Post SEQadmin2  
          Started by SEQadmin2, 07-24-2026, 12:17 PM
          0 responses
          10 views
          0 reactions
          Last Post SEQadmin2  
          Started by SEQadmin2, 07-23-2026, 11:41 AM
          0 responses
          11 views
          0 reactions
          Last Post SEQadmin2  
          Started by SEQadmin2, 07-20-2026, 11:10 AM
          0 responses
          23 views
          0 reactions
          Last Post SEQadmin2  
          Working...